Gaber, M., Alhashemee, M., Hassan, A., Hammam, S. (2019). Concomitent Chemotherapy and radiotherapy in patients with Locally Advanced Rectal Carcinoma. test, 23(Issue 1), 209-214. doi: 10.21608/smj.2019.43498
Mohmed Soliman Gaber; Mohamed Abo Elmagd Alhashemee; Al Sayed M Hassan; Sahar Noor Eldeen Hammam. "Concomitent Chemotherapy and radiotherapy in patients with Locally Advanced Rectal Carcinoma". test, 23, Issue 1, 2019, 209-214. doi: 10.21608/smj.2019.43498
Gaber, M., Alhashemee, M., Hassan, A., Hammam, S. (2019). 'Concomitent Chemotherapy and radiotherapy in patients with Locally Advanced Rectal Carcinoma', test, 23(Issue 1), pp. 209-214. doi: 10.21608/smj.2019.43498
Gaber, M., Alhashemee, M., Hassan, A., Hammam, S. Concomitent Chemotherapy and radiotherapy in patients with Locally Advanced Rectal Carcinoma. test, 2019; 23(Issue 1): 209-214. doi: 10.21608/smj.2019.43498

Concomitent Chemotherapy and radiotherapy in patients with Locally Advanced Rectal Carcinoma

Sohag Medical Journal
Article 33, Volume 23, Issue 1, January 2019, Pages 209-214    PDF (270.6 K)
Document Type: Original Article
DOI: 10.21608/smj.2019.43498
Authors
Mohmed Soliman Gaber1; Mohamed Abo Elmagd Alhashemee2; Al Sayed M Hassan3; Sahar Noor Eldeen Hammam4
1Department of Clinical Oncology , Faculty of Medicine, Sohag University.
2Department of surgical oncology , south Egypt cancer Institute
3Department of Clinical oncology, Faculty of Medicine, Sohag University, Sohag, Egypt.
4Department of oncology, Faculty of Medicine, Sohag University.
Abstract
Introduction:In recent years, the approach to adjuvant therapy for rectal cancer in the United States and Europe has been shifting toward preoperative therapy to promote sphincter-preserving surgery and decrease acute and late bowel toxicity.
Patients&Methods:This study will be a phase II trial to study the effectiveness of combining chemotherapy (Gemcitabine) and external – beam radiotherapy followed by surgery in treating patients who have locally advanced rectal cancer , It is carried on Sohag University Hospital & Sohag NCI since( October 2014- December2017),the dose of radiotherapy 5040 cGy /28ttt,and chemotherapy dose is 45mg/m2 given twice weekly during radiotherapy sessions only,  the study included 30 patients (age 18 and over), having rectal cancer with the following eligibility criteria:histologically proven ,previously untreated rectal carcinoma , every patient in the study was subjected to the following:history & physical examination,laboratory investigations, radiological studies.
 Results:Thirty patients were included in the study,13 females (43.3%) and 17 male( 56.6%)     mean of the age was 49 years. (range24-65year), most of them had adenocarcinoma of the rectum, the main presenting symptom was bleeding per rectum(56.7%), as regard to the response to the neoadjuvant treatmen 12/30 patients (40%) achieved Partial response,  8/30patients(27.6%) achieved complete  response and 10/30 patients (33%) had no response, abdomino - perineal resection was performed in 19 patients(63.3%)  and 11 patients (36.7%)  underwent sphincter preservation operation, about the toxicity in this study,for chemotherapy diarrhea was the most common manifestation which seen in 25 patients(83%),followed by loss of appetite seen in 9 patients(63.3%), for radiotherapy 19 patients (63%) developed wet desquamation. the  rate of Overall Survival of  the 2-years study is (80%),the Disease free survival is (63%)while the progression free survival is (72%),N stage was the only significant factor affecting the disease free survival and overall survival.
Conclusion: Pre-operative chemo-radiotherapy in dose and fractionation schedule used is safe, effective and well tolerated, allowed sphincter preservation which performed in (36.7%) of patients
Supplementary Files
References
  1.  Jakobsen A, Ploen J, Vuong T, Appelt A, Lindebjerg J, Rafaelsen SR. Dose-Effect Relationship in Chemoradiotherapy for Locally Advanced Rectal Cancer: A Randomized Trial Comparing Two Radiation Doses. Int J Radiat Oncol Biol Phys. 2012 May 15.
  2. Kahi CJ, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T. Colonoscopy Surveillance After Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2016 Mar. 150 (3):758-768.e11.
  3. Levin B, Lieberman DA, McFarland B . Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008; 134:1570
  4. Meredith KL, Hoffe SE, Shibata D. The multidisciplinary management of rectal cancer. Surg Clin North Am. 2009 Feb. 89(1):177-215, ix-x.                                  Mini, E; Nobili, S; Caciagli, B; Landini, I; Mazzei, T (May 2006). "Cellular pharmacology of gemcitabine". Annals of Oncology.
  5. Mork ME, You YN, Ying J. High Prevalence of Hereditary Cancer Syndromes in Adolescents and Young Adults With Colorectal Cancer. J Clin Oncol 2015; 33:35
  6. Klabunde CN, Cronin KA, Breen N. Trends in colorectal cancer test use among vulnerable populations in the United States. Cancer Epidemiol Biomarkers Prev 2011; 20:161
  7. Wu S, Feng B, Li K. Fish consumption and colorectal cancer risk in humans: a   systematic review and meta-analysis. Am J Med 2012; 125:551
  8. Y Kanemitsu, T. Kato, T. Hirai et al., “Survival after curative resection for     mucinous adenocarcinoma of the colorectum,” Diseases of the Colon and Rectum, vol. 46, no. 2, pp. 160-167 2003
  9. van Helmond J, Beart RW. Cancer of the rectum: Operative management and adjuvant therapy. Current Therapy in Colon and Rectal Surgery. 2nd ed. Philadelphia, Pa: Mosby; 2005.
 

 

 

 

 

 

 

Statistics
Article View: 217
PDF Download: 262